EATONTOWN, N.J., Nov. 5 /PRNewswire/ -- Roberts Pharmaceutical Corporation
(Amex: RPC) announced today that Louis P. Berardi, formerly of Hoechst Marion
Roussel, has joined Roberts as Senior Vice President, New Business Development
and Strategic Planning, a newly created position reporting directly to John T.
Spitznagel, Roberts President and CEO.
    Before joining Roberts, Mr. Berardi held senior positions in new business
development and strategic planning with SmithKline Beecham, PLC, Carter-
Wallace, Inc., and most recently with Hoechst Marion Roussel where he was a
member of the management team involved in analyzing and implementing Hoechst's
1995 purchase of Marion Merrell Dow.  In these prior positions, Mr. Berardi's
responsibilities encompassed identifying, evaluating, and executing strategies
involving corporate alliances, co-promotions, joint ventures, emerging
technologies, pipeline acquisitions, and product licensing opportunities.  Mr.
Berardi received his Bachelor of Arts and a MBA in Finance and Economics from
Fairleigh Dickinson University.
    Commenting on today's announcement, John T. Spitznagel said, "Lou possess
over twenty years of invaluable experience in new business development and
strategic planning, both in the national and international arenas.  We are
very pleased that he has decided to join our Company and become a member of
Roberts senior management staff."
    Roberts Pharmaceutical Corporation, with operating subsidiaries in the
United States, Canada, and the United Kingdom, focuses on licensing,
acquiring, developing and commercializing innovative pharmaceuticals in
selected therapeutic categories.  The Company's first pipeline product,
ProAmatine(R) was recently launched in the US as the first FDA cleared drug to
treat orthostatic hypotension.  Agrylin(TM), Roberts second pipeline product,
has since been launched in the US as the first drug cleared to treat essential
thrombocythemia and is currently under review for approval in Canada and the
European Union.
    This and past press releases of Roberts Pharmaceutical Corporation are
available through PR Newswire's Company News On-Call fax service at
1-800-758-5804, extension 760975 and on the internet at
http://www.prnewswire.com and http://www.robertspharm.com .

    This release may contain forward-looking statements which reflect
management's current views of future events and operations.  These
forward-looking statements are based on assumptions and external factors,
including assumptions relating to regulatory action and competing products.
Any changes in such assumptions or external factors could produce
significantly different results.

Link to this page: